Abstract
Multidrug-resistant (MDR) tuberculosis is an important medical and public health challenge, afflicting an estimated 500 000 new patients each year. Recent progress in the development of new molecular diagnostic techniques and the first new antituberculosis drug registration in almost 40 years 2
provide reasons for optimism, but still, globally, less than 10% of individuals with MDR-tuberculosis receive treatment of known quality.
